Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras^G12D in pancreatic cancer.

Corroborating the trend of suppressed tumor growth seen with bioluminescent imaging, we also noted a trend for reduced levels of Kras G12D mRNA in the group treated with exosomes containing Cas9/ Kras G12D sgRNA1 plasmid relative to all other groups, which however did not reach statistical significance ( Fig 4B ).

also in 111,027 other papers